Almac announces £27m global expansion

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/scanrail)
(Image: iStock/scanrail)

Related tags Almac group

The Almac Group is planning to expand its operations in Europe and North America with an investment totaling £27m across three sites.

The largest portion of the investment is a £20m expansion at the company’s Souderton, Pennsylvania-based headquarters. The money will help expand the existing 240,000-square-foot facility in addition to leasing a 26,000-square-foot office space in nearby Lansdale.

The announcement comes on the heels of the company’s £4.2m expansion​ at its facility in North Carolina.

Almac’s continued growth comes as a direct result of the continued drive to both meet and exceed the needs of our customers​,” Almac CEO and Chairman Alan Armstrong told

Across the companies there is an increased demand for the excellence that Almac can provide combined with a focus on the customer, leading to a requirement for growth in employee numbers and also investment in the latest equipment, facilities etc. in order to maintain our competitive edge​,” he added.

Armstrong explained the expansion is across a range of Almac’s business units, including clinical services, clinical technologies, pharma services, and sciences.

The jobs to be created span a wide range of functions including administrative, HR, scientific, management and operations​,” he said, adding that this will enable Almac to continue “to provide high quality customer-centric services across all our business units​.”

In addition to the £20 million investment in Pennsylvania, the company is also devoting £5m to build additional laboratory and office space at its global headquarters in Craigavon, Northern Ireland. Around 170 existing employees will be transferred to the new building.

Another £2m will help develop the Arran Chemical Company facility in Athlone, Ireland which Alamc was acquired last year.

According to the company, the project enables the upgrade of existing site infrastructure and brings additional manufacturing capacity as well as added distillation and drying capabilities.

Upon completion, the Almac Group expects to increase its global headcount from 4,600 to 5,000 by the end of 2017.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more